Lay out the future EGFR-TKI three generation market, and Beida Pharmaceutical Co., Ltd. will benefit from RMB 230 million of patents in the cooperation area of bio-d-0316

On December 27, Beida pharmaceutical announced that it had held the 30th meeting of the second board of directors, deliberated and passed the proposal on cooperation with Yifang bio on d-0316 project, the company signed the cooperation agreement with Yifang Bio Technology (Shanghai) Co., Ltd (hereinafter referred to as "Yifang bio"), and Beida pharmaceutical transferred d-0316 The Chinese rights and interests of the project (including Mainland China, Hong Kong and Taiwan) and exclusive development and commercialization of d-0316 products in the agreed area The announcement pointed out that in order to enrich the R & D product pipeline and lay out the future EGFR-TKI three generation market, through friendly consultation, Beida pharmaceutical and Yifang biology carried out cooperation on the d-0316 project D-0316 is a third-generation EGFR-T790M tyrosine kinase inhibitor Yifang biology has its patent, patent application right and proprietary technology, and is currently in phase I clinical trial in China Beida pharmaceutical will pay the down payment and subsequent R & D milestone to Yifang bio, totaling 23 million yuan, plus sales commission after the product goes on the market The patent and patent application rights and know-how of the d-0316 related cooperation areas (including Mainland China, Hong Kong and Taiwan) owned by yifangbio are transferred, and the joint patent is exclusively implemented by beidaye in the cooperation area to develop, manufacture and commercialize d-0316 and its products In August 2016, bpi-15086, a new Baida pharmaceutical drug with T790M mutation, entered the clinical trial (approval No.: 2016l07080, 2016l07081) and is currently in the phase I clinical stage According to the comprehensive evaluation of Beida pharmaceutical, compared with the similar products in the market and under development, the d-0316 project has more competitive advantages than the bpi-15086 project Beida pharmaceutical decided to suspend the further research and development of the bpi-15086 project and fully promote the research and development of the d-0316 project As the first generation of EGFR-TKI drugs, the existing products of Beida Pharmaceutical Co., Ltd ektinib were approved to be listed in China by the State Drug Administration in 2011, and gained good reputation in the market, which also accumulated rich experience and resources in the field of lung cancer treatment The successful introduction of d-0316 will give full play to the long-term clinical research and marketing experience of Beida pharmaceutical, further enrich its R & D pipeline, and help Beida pharmaceutical to form a multi-level lung cancer treatment drug product line in the future According to the announcement, Beida pharmaceutical adheres to the enterprise development concept of "independent intellectual property rights innovation drug research and development as the core", especially for the research and development of new drugs for malignant tumors Through the combination of independent research and development and strategic cooperation, it continuously increases the reserve of new drug projects, laying the foundation for its deep development in the anti-tumor drug market, and improving the future market competitiveness of the company 。 The following is the original announcement: